Darifenacin Tablet, Extended Release
Product Images NDC 46708-223

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Darifenacin (NDC 46708-223). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30's Bottle Pack (Darifenacin 15mg)

Label for Darifenacin Extended-Release Tablets, 15 mg strength, oral dosage form. The label includes drug storage instructions, usual dosage recommendations, and manufacturer details from Alembic Pharmaceuticals Limited, India. The package contains 30 tablets and displays NDC 46708-224-30 with barcode.*

FDA Label Image

30's Bottle Pack (Darifenacin 75mg)

Label for Darifenacin Extended-Release Tablets 7.5 mg by Alembic Pharmaceuticals Limited. The label indicates 30 tablets per bottle with instructions to store at controlled room temperature and protect from light. It includes NDC 46708-223-30, manufacturer details, and states the dosage strength as 7.5 mg.*

FDA Label Image

Figure 1 (Darifenacin Figure1)

A pharmacokinetic curve showing mean darifenacin plasma concentration (ng/mL) over 24 hours post-dose. It compares two extended release tablet doses, 7.5 mg and 15 mg once daily, with concentration on the vertical axis and time post-dose (hours) on the horizontal axis. Error bars indicate standard deviation.*

FDA Label Image

Figure 2a (Darifenacin Figurea2)

A line graph showing median reduction in incontinence episodes per week from baseline over 12 weeks. The graph compares Placebo, Darifenacin 7.5 mg, and Darifenacin 15 mg dosages. The vertical axis indicates median reduction percentage, and the horizontal axis represents time in weeks. Data points include error bars representing 95 percent confidence intervals.*

FDA Label Image

Figure 2b (Darifenacin Figureb2)

A line graph depicting the median reduction in incontinence episodes per week from baseline over 12 weeks, comparing placebo, Darifenacin 7.5 mg, and Darifenacin 15 mg. The graph shows data points with error bars for each treatment at weeks 0, 2, 6, and 12, indicating greater reduction with Darifenacin doses compared to placebo.*

FDA Label Image

Figure 2c (Darifenacin Figurec2)

A line chart comparing the median reduction in incontinence episodes per week from baseline over 12 weeks for placebo and Darifenacin 15 mg extended-release tablets. The y-axis shows the median reduction (with 95% confidence intervals), and the x-axis shows time in weeks. Data points indicate greater reduction for Darifenacin compared to placebo at all measured intervals.*

FDA Label Image

Structure (Darifenacin Str)

Chemical structure of the active ingredient darifenacin, showing its molecular arrangement including benzofuran and piperidine rings, phenyl groups, and an ammonium salt form (HBr).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.